Monday, January 19, 2026 2:10:37 PM
beartrap12,
I find the regional partnership mention really interesting because most deals are made with the U.S. and the rest of world (ROW) market considerations. With NWBO seeking their first approval in the UK, maybe this time there will be a different twist with those considerations. UK wants to be a tech leader especially since their departure from the EU. I believe AZN still has some significant interest in NWBO and that Mr. Neil Woodford was kind of trying to aim for that kind of connection since he lent money to NWBO for the Sawston site development. The physical distance between NWBO at Sawston and AZN in Cambridge is just a few miles. AZN definitely knows what is going on at Sawston with a potential partner or competitor like NWBO and obviously they have plenty of connections in the area. A regional development partnership in the UK would make sense for those concerned about the economic impact of loosing out long term to other foreign based pharmas especially since NWBO has a patent granted for the combo there as I recall. While the U.S. patent office fools around, perhaps with big pharma influence in mind, the UK can take the lead with approved product combo opportunities. Since AZN is a joint British and Swiss venture maybe the bears will finally have their answer about what happened with the “Swiss approval”. Just needed a UK sign off; ). Best wishes.
I find the regional partnership mention really interesting because most deals are made with the U.S. and the rest of world (ROW) market considerations. With NWBO seeking their first approval in the UK, maybe this time there will be a different twist with those considerations. UK wants to be a tech leader especially since their departure from the EU. I believe AZN still has some significant interest in NWBO and that Mr. Neil Woodford was kind of trying to aim for that kind of connection since he lent money to NWBO for the Sawston site development. The physical distance between NWBO at Sawston and AZN in Cambridge is just a few miles. AZN definitely knows what is going on at Sawston with a potential partner or competitor like NWBO and obviously they have plenty of connections in the area. A regional development partnership in the UK would make sense for those concerned about the economic impact of loosing out long term to other foreign based pharmas especially since NWBO has a patent granted for the combo there as I recall. While the U.S. patent office fools around, perhaps with big pharma influence in mind, the UK can take the lead with approved product combo opportunities. Since AZN is a joint British and Swiss venture maybe the bears will finally have their answer about what happened with the “Swiss approval”. Just needed a UK sign off; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
